

研究成果の刊行に関する一覧表

書籍

| 著者氏名 | 論文タイトル名 | 書籍全体の編集者名 | 書 籍 名 | 出版社名 | 出版地 | 出版年 | ページ |
|------------|---------------|-----------------------------|---------------------------------|--------|-------|------|---------|
| 高首根健, 関島良樹 | 脳腱黄色腫症 | 水澤英洋, 五十嵐隆, 北川泰久, 高橋和久, 弓倉整 | 指定難病ペディア2019 | 日本医師会 | 東京 | 2019 | 275-276 |
| 土橋一重 | 家族性高コレステロール血症 | 五十嵐隆 | 小児科診療ガイドライン第4版 | 総合医学社 | 東京 | 2019 | 528-532 |
| 三井田孝 | 低HDL-C血症 | 磯部光章, 竹本稔, 前嶋康浩, 弓倉整, 横手幸太郎 | 動脈硬化診療のすべて | 日本医師会 | 日本医師会 | 2019 | S94-S97 |
| 小倉正恒 | LDL-Cを下げる | 伊藤浩 | そうだったんだ! 脂質異常省第2版 | 文光堂 | 東京 | 2020 | 160-173 |
| 塚本和久 | シトステロール血症 | 水澤英洋, 五十嵐隆, 北川泰久, 高橋和久, 弓倉整 | 指定難病ペディア2019, 日本医師会雑誌生涯教育シリーズ96 | 診断と治療社 | 東京 | 2019 | 280 |
| 塚本和久 | 高LDLコレステロール血症 | 片山茂裕, 猿田享男 | 私の治療 | 日本医事新報 | 東京 | 2019 | 42 |
| 塚本和久 | 高トリグリセライド血症 | 片山茂裕, 猿田享男 | 私の治療 | 日本医事新報 | 東京 | 2019 | 43 |
| 内野卓也, 塚本和久 | 脂質異常症の病態と診断 | 伊藤浩 | そうだったんだ! 脂質異常症 | 文光堂 | 東京 | 2020 | 77-82 |

| | | | | | | | |
|------|-----------|------|---|--------------------|----|------|---------------|
| 塚本和久 | シトステロール血症 | 永井良三 | 今日の診断指 針 第8版 | 医学書院 | 東京 | 2020 | 1199-120 1 |
| 小山信吾 | 脳腱黄色腫症 | | Current Decision Support 『今 日の疾患辞 典』 デジタル版 | 株式会社 プレシジ ョン | | 2019 | |

雑誌

| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | ページ | 出版年 |
|---|--|----------------------------------|----|-----|-----|
| <p>Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M, Almahmeed W, Alonso R, Al-Rasadi K, Badioumon L, Bernal LM, Bogsrud MP, Braun LT, Brunham L, Catapano AL, Cillikova K, Corral P, Cuevas R, Defesche JC, Descamps OS, de Ferranti S, Eisele JL, Elikir G, Folco E, Freibergert T, Fuggetta F, Gaspar IM, Gesztes AG, Groselj U, Hamilton-Craig I, Hanauer-Mader G, <u>Harada-Shiba M</u>, Hastings G, Hovingh GK, Izar MC, Jamison A, Karlsson GN, Kayikcioglu M, Koob S, Koseki M, Lane S, Lima-Martinez MM, Lopez G, Martinez TL, Marais D, Marion L, Mata P, Maurina I, Maxwell D, Mehta R, Mensah GA, Mizer ez AR, Neely D, Nicholls SJ, Nohara A, Nordestgaard BG, Ose L, Pallidis A, Pang J, Payne J, Peterson AL, Popescu MP, Puri R, Ray KK, Reda A, Sampietro T, Santos RD, Schalkers I, Schreier L, Shapiro MD, Sijbrands E, Soffer D, Stefanutti C, Stoll M, Sy RG, Tamayo ML, Tilney MK, Tokgozogl u L, Tomlinson B, Vallejo-Vaz AJ, Vazquez-Cardenas A, de Luca PV, Wald DS, Watts GF, Wenger NK, Wolf M, Wood D, Zegerius A, Gaziano TA, Gidding SS.</p> | <p>Reducing the clinical and public health burden of familial hypercholesterolemia: A global call to action.</p> | <p>JAMA cardiology. in press</p> | | | |

| | | | | | |
|---|--|--|--------|-----------|------|
| Ota-Kontani A, Hirata H, Ogura M, Tsuchiya Y, <u>Harada-Shiba M.</u> | Comprehensive analysis of mechanism underlying hypouricemic effect of glucosyl hesperidin. | Biochem Biophys Res Commun | 521 | 861-867 | 2020 |
| Otani K, Tokudome T, Kamiya CA, Muro Y, Nishimura H, Hasegawa T, Arisai Y, Kaneko M, Shimoi G, Ishida J, Fukumizu A, Osaki T, Nagai-Okatani C, Minamino N, Ensho T, Hino J, Murata S, Takegami M, Nishimura K, Kishimoto I, Miyazato M, <u>Harada-Shiba M.</u> , Yoshimatsu J, Nakao K, Ikeda T, Kangawa K. | Deficiency of cardiac natriuretic peptide signaling promotes peripartum cardiomyopathy-like remodeling in the mouse heart. | Circulation | 141(7) | 571-588 | 2020 |
| Harada-Shiba M | What arteries are affected in familial hypercholesterolemia? | Journal of Atherosclerosis and Thrombosis | 26 | 1041-1042 | 2019 |
| Yamamoto T, Sawamura M, Terada C, Kashiwada K, Wada F, Yamayoshi A, Obika S, <u>Harada-Shiba M.</u> | Effect of modular conjugation strategy for n-acetylgalactosamine-targeted antisense oligonucleotides. | Nucleosides, Nucleotides and Nucleic Acids | 16 | 1-10 | 2019 |
| Yamamoto T, Terada C, Kashiwada K, Yamayoshi A, <u>Harada-Shiba M.</u> , Obika S. | Synthesis of Monovalent N-Acetylgalactosamine Phosphoramidite for Liver-Targeting Oligonucleotides. | Curr Protoc Nucleic Acid Chem | 78(1) | e99 | 2019 |
| Hori M, Ohta N, Takahashi A, Masuda H, Isoda R, Yamamoto S, Son C, Oogura M, Hosoda K, Miyamoto Y, <u>Harada-Shiba M.</u> | Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients | Atherosclerosis | 289 | 101-108 | 2019 |

| | | | | | |
|--|--|---|--------------|-----------|---------|
| Suzuki T, Wakao Y, Watanabe T, Horii M, Ikeda Y, Tsuchiya H, Kogure K, <u>Harada-Shiba M</u> , Fujimuro M, Kamiya H, | No enhancing effects of plasmid-specific histone acetyltransferase recruitment system on transgene expression in vivo | Nucleosides Nucleotides Nucleic Acids | 38(12) | 942-949 | 2019 |
| Makino H, Kozuka R, Tamanaha T, Ogura M, Matsuki K, Hosoda K, <u>Harada-Shiba M</u> . | Familial Hypercholesterolemia and Lipoprotein Apheresis | J Atheroscler Thromb | 26(8) | 679-687 | 2019 |
| Shibata MA, <u>Harada-Shiba M</u> , Shibata E, Tosa H, Matoba Y, Hamaoka H, Iinuma M, Kondo Y. | Crude α -Mangostin Suppresses the Development of Atherosclerotic Lesions in Apoe-Deficient Mice by a Possible M2 Macrophage-Mediated Mechanism. | Int J Mol Sci | 20(7) | | 2019 |
| <u>Harada-Shiba M</u> | How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia? | Atherosclerosis | 284 | 218-220 | 2019 |
| Otani K, Kamiya A, Miyazaki T, Kogawa A, Inatomi A, <u>Harada-Shiba M</u> , | Surface Modification with Lactadherin Augments the Attachment of Sonozoid Microbubbles to Glycoprotein IIb/IIIa, | Ultrasound Med Biol | 45(6) | 1455-1465 | 2019 |
| 小倉正恒, 斯波真理子 | 家族性高コレステロール血症 | 動脈硬化診療のすべて日本医師会雑誌 | 第148巻・特別号(2) | S11-S12 | 2019.10 |
| 小倉正恒 | 低LDLアフェレシス | 動脈硬化診療のすべて日本医師会雑誌 | 第148巻・特別号(2) | S256-S258 | 2019.10 |
| 小倉正恒, 斯波真理子 | エボロクマブ・アリロクマブ, ロミタピド, ペマフィブラート | Current Therapy | Vol.37 No.10 | 78-82 | 2019.10 |

| | | | | | |
|---|--|---|----|-----------|------|
| Shimada, K., Nishitani-Yokoyama, M., Takahashi, T. & Daida, H. | Physical activity and long-term prognosis in patients with stable coronary artery disease: How often, how intense, and how long? | European journal of preventive cardiology | 27 | 422-425 | 2020 |
| Toyota, T., Morimoto, T., Iimuro, S., Iatani, H., Miyauchi, K., Inoue, T., Naito, K., Ozaki, Y., Sakuma, I., Furukawa, Y., Ohashi, Y., Matsuzaki, M., Nagai, R. & Kimura, T. | LDL-C levels on statins and cardiovascular event risk in stable coronary artery disease: An observation from the REAL-CAD study | European Heart Journal | 40 | 433-433 | 2019 |
| Shitara, J., Kasai, T., Konishi, H., Endo, H., Wada, H., Doi, S., Naito, R., Tsuboi, S., Ogita, M., Dohi, T., Okazaki, S., Miyauchi, K. & Daida, H. | Impact of Lipoprotein (a) Levels on Long-Term Outcomes in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction. | Circulation Journal | 83 | 1047-1053 | 2019 |
| Sai, E., Shimada, K., Yokoyama, T., Hiki, M., Aikawa, T., Ouchi, S., Aoshima, C., Kawaguchi, Y., Miyazaki, T., Fujimoto, S., Tamura, Y., Aoki, S., Watanabe, H., Kawamoto, R. & Daida, H. | Associations between ectopic fat accumulations and cardiovascular-metabolic factors in apparently healthy subjects: assessed by 1H-magnetic resonance spectroscopy in myocardium, liver, and skeletal muscles. | European Heart Journal-Cardiovascular Imaging | 20 | 154-154 | 2019 |
| Kitamura, K., Isoda, K., Akita, K., Miyasawa, K., Kadoguchi, T., Shimada, K. & Daida, H. | Lack of IkB β promotes cholate-containing high-fat diet-induced inflammation and atherogenesis in low-density lipoprotein (LDL) receptor-deficient mice. | European Heart Journal | 40 | 2495-2495 | 2019 |

| | | | | | |
|---|--|---|----|---------|------|
| Itoh, H., Komuro, I., Takeuchi, M., Akasaka, T., Daida, H., Egashira, Y., Fujita, H., Higaki, J., Hirata, K., Ishibashi, S., Isshiki, T., Ito, S., Kashiwagi, A., Kato, S., Kitagawa, K., Kitakaze, M., Kitazono, T., Kurabayashi, M., Miyauchi, K., Murakami, T., Murahara, T., Node, K., Ogawa, S., Saito, Y., Seino, Y., Shigeeda, T., Shindo, S., Sugawara, M., Sugiyama, S., Terauchi, Y., Tsutsui, H., Ueshima, K., Utsunomiya, K., Yamagishi, M., Yamazaki, T., Yo, S., Yokote, K., Yoshida, K., Yoshimura, M., Yoshimura, N., Nakao, K. & Nagai, R. | Achieving LDL cholesterol target levels < 1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study. | Diabetes Obesity & Metabolism | 21 | 791-800 | 2019 |
| Endo, H., Dohi, T., Miyauchi, K., Kuramitsu, S., Kato, Y., Okai, I., Yokoyama, M., Yokoyama, T., Ando, K., Okazaki, S., Shimada, K., Suwa, S. & Daida, H. | Clinical significance of non-culprit plaque regression following acute coronary syndrome: A serial intravascular ultrasound study. | Journal of Cardiology | 74 | 102-108 | 2019 |
| Daida, H., Dohi, T., Fukushima, Y., Ohmura, H. & Miyauchi, K. | The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials. | Journal of Atherosclerosis and Thrombosis | 26 | 592-600 | 2019 |
| Daida, H. | Twenty- years History of the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine | Juntendo Medical Journal | 66 | 2-9 | 2020 |

| | | | | | |
|--|--|-----------------------|----|-----------|------|
| Tada H, Okada H, Nomura A, Yashiro S, Nohara A, Ishigaki Y, Takamura M, Kawashiri MA | Rare and Deleterious Mutations in ABCG5/ABCG8 Genes Contribute to Mimicking and Worsening of Familial Hypercholesterolemia Phenotype | Circulation J | 83 | 1917-1924 | 2019 |
| Tada H, Okada H, Nomura A, Takamura M, Kawashiri MA | Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene | Lipids Health Dis | 19 | 3 | 2020 |
| Nohara A, Otsubo Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, Jurecka A: | Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study. | J Atheroscler Thromb | 26 | 368-377 | 2019 |
| Kameyama N, Maruyama C, Kitagawa F, Nishii K, Ueno M, Komachi K, Katayama Y, Koga H, Chikamoto N, Kuwata Y, Torigoe J, Arimoto M, Tokumaru T, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, Harada-Shiba M.: | Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia. | J Atheroscler Thromb. | 26 | 72-83 | 2019 |
| Komatsu T, Sakurai T, Wolska A, Amaral MJ, Sakurai A, Vaisman BL, Sviridov D, Demosky S, Pryor M, Ikewaki K, Remaley AT | Apolipoprotein C-II Mimetic Peptide Promotes the Plasma Clearance of Triglyceride-Rich Lipid Emulsion and the Incorporation of Fatty Acids into Peripheral Tissues of Mice | J Nutr Metab | | | 2019 |

| | | | | | |
|--|---|--------------------------------|-------|---------------------------------------|------|
| Sasaki M, Komatsu T, Ikewaki K | Impact of Hepatic ABCA1 (ATP-Binding Cassette Transporter A1) Deletion on Reverse Cholesterol Transport: A New Clue in Solving Complex HDL (High-Density Lipoprotein) Metabolism. | Arterioscler Thromb Vasc Biol. | 39(9) | 1699-1701 | 2019 |
| Yoshida H, Tada H, Ito K, Kishimoto Y, Yanai H, Okamura T, Ikewaki K, Inagaki K, Shoji T, Bujo H, Miida T, Yoshida M, Kuzuya M, Yamashita S. | Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals. | J Atheroscler Thromb. | | | 2019 |
| Ezaki H, Matsuura T, Ayaori M, Ochi S, Mezaki Y, Masaki T, Taniwaki M, Miyake T, Sakurada M, Ikewaki K. | The fasting (13)C-glucose breath test as a more sensitive evaluation method for diagnosing hepatic insulin resistance as a cardiovascular risk factor than HOMA-IR. | Clin Chim Acta. | 500 | 20-27 | 2020 |
| Kouji Kajinami, Asuka Ozaki, Yuki Tajima, Shizuya Yamashita, Hidenori Arai, Tamio Teramoto | Real-world data to identify hypercholesterolemia patients on suboptimal statin therapy | J Atheroscler Thromb | 26(5) | 408-431 | 2019 |
| Koutaro Yokote, Shizuya Yamashita, Hidenori Arai, Eiichi Araki, Hideki Suganami, Shun Ishibashi, on behalf of the K-877 Study Group | Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor α -modulator (SPPARM α), in dyslipidemic patients with renal impairment | Int J Mol Sci | 20(3) | pii: E706. doi: 10.3390/ijms20030706. | 2019 |

| | | | | | |
|---|--|--------------------------------------|--------------|----------------|-------------|
| <p>Ian J. Neeland, Robert Ross, Jean-Pierre Després, Yuji Matsuzawa, Shizuya Yamashita, Iris Shai, Jaap Seidell, Paolo Magni, Raul D. Santos, Benoit Arsenault, Ada Cuevas, Frank B. Hu, Bruce Griffin, Alberto Zambon, Philipp Barter, Jean-Charles Fruchart, Robert Eckel</p> | <p>Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: A Joint Position of the International Atherosclerosis Society and International Chair on Cardio-metabolic Risk Working Group on Visceral Obesity</p> | <p>Lancet Diabetes Endocrinology</p> | <p>7(9)</p> | <p>715-725</p> | <p>2019</p> |
| <p>Takeshi Okada, Toru Ohama, Kazuaki Takafuji, Kotaro Kanno, Hibiki Matsuda, Masami Sai-ryo, Yinghong Zhu, Ayami Saga, Takuya Kobayashi, Da- isaku Masuda, Masahiro Koseki, Makoto Nishida, Yasushi Sakata, Shizuya Yamashita</p> | <p>Shotgun proteomic analysis reveals proteome alterations in HDL of patients with cholesteryl ester transfer protein deficiency</p> | <p>J Clin Lipidology</p> | <p>13(2)</p> | <p>317-325</p> | <p>2019</p> |
| <p>Atsushi Hirayama, Shizuya Yamashita, Andrea Ruzza, Masahito Inomata, Marcolini Cyrille, Chen Lu, Andrew Hameed, Masayuki Yoshida, Arihiro Kiyosue, Tamio Teramoto</p> | <p>Long-term treatment of evolocumab among Japanese patients: final report of the OSLER open-label extension studies (Pub-Id-074860)</p> | <p>Circ J</p> | <p>83(5)</p> | <p>971-977</p> | <p>2019</p> |

| | | | | | |
|---|--|-----------------------------|---------------|----------------|-------------|
| <p>Jing Pang, Dick C Chan, Miao Hu, Lauretta A Muir, Seung Kwok, Min-Ji Charnng, Christopher M Florkowski, Peter George, Jie Lin, A David Marais, Hapizah M Nawawi, Lourdes E Gonzalez-Santos, Ta-Chen Su, Thanh Huong Truong, Raul D Santos, Handrean Soran, Brian Tomlinson, Shizuya Yamashita, Zanfina Ademi, Gerald F Watts</p> | <p>Comparative aspects of the care of familial hypercholesterolaemia in the “Ten Countries Study”</p> | <p>J Clin Lipidol</p> | <p>13(2)</p> | <p>287-300</p> | <p>2019</p> |
| <p>Jingyi Liu, Makoto Nishida, Hiroyasu Inui, Jiuyang Chang, Yinghong Zhu, Kotaro Kanno, Hibiki Matsuda, Masami Sairyo, Takeshi Okada, Hajime Nakaoka, Tohru Ohama, Daisaku Matsuda, Masahiro Koseki, Shizuya Yamashita, Yasushi Sakata</p> | <p>Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction</p> | <p>J Atheroscler Thromb</p> | <p>26(10)</p> | <p>915-930</p> | <p>2019</p> |

| | | | | | |
|--|---|-----------------------------------|--------------|-----------|-------------|
| <p>Jean-Charles Fruchart, Raul D Santos, Carlos Aguilar-Salinas, Masanori Aikawa, Khalid Al Rasadi, Pierre Amarenco, Philip J Barter, Richard Ceska, Alberto Corsini, Jean-Pierre Després, Patrick Duriez, Robert H Eckel, Marat V Ezhov, Michel Farnier, Henry N Ginsberg, Michel P Hermans, Shun Ishibashi, Fredrik Karpe, Tatsuhiko Kodama, Wolfgang Koenig, Michel Krempef, Soo Lim, Alberto J Lorenzatti, Ruth McPherson, Jesus Millan Nuñez-Cortes, Børge G Nordestgaard, Hisao Ogawa, Chris J Packard, Jorge Plutzky, Carlos I Ponte-Negetti, Aruna Pradhan, Željko Reiner, Paul M Ridker, Massimo Ruscica, Shaukat Sadikov, Hitoshi Shimano, Piyamitr Sritara, Jane K Stock, Ta-Chen Su, Andrey V Susekov, André Tartar, Marja-Riitta Taskinen, Alexander Tenenbaum, Lale S Tokgözoğlu, Brian Tomlinson, Anne Tybjærg-Hansen, Paul Valensi, Michal Vrablík, Walter Wahli, Gerald F Watts, Shizuya Yamashita, Koutaro Yokote, Alberto Zambon, Peter Libby</p> | <p>The selective peroxisome proliferator-activated receptor alpha modulator (SPARMA) paradigm: Conceptual framework and therapeutic potential. A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation</p> | <p>Cardiovascular Diabetology</p> | <p>18(1)</p> | <p>71</p> | <p>2019</p> |
|--|---|-----------------------------------|--------------|-----------|-------------|

| | | | | | |
|--|--|-------------------------------|----------------|------------------|-------------|
| <p>Eiichi Araki, Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Jo Satoh, Toyoshi Inoguchi, Jiro Nakamura, Hiroshi Maegawa, Naruhiko Tanizawa, Hirofumi Tanizawa, Hideki Suganami, Shun Ishibashi</p> | <p>Efficacy and safety of pemafibrate in patients with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE Study</p> | <p>Diabetes Obesity Metab</p> | <p>21(7)</p> | <p>1737-1744</p> | <p>2019</p> |
| <p>Jean-Charles Fruchart, Raul D. Santos, Shizuya Yamashita, Peter Libby; International Atherosclerosis Society/R3i Foundation Consensus Panel</p> | <p>Residual vascular risk in diabetes - Will the SPPARM algorithm concept hold the key?</p> | <p>Diabetes Metab Syndr</p> | <p>13(4)</p> | <p>2723-2725</p> | <p>2019</p> |
| <p>Yasuyoshi Ouchi, Jun Sasaki, Hidenori Arai, Koutaro Yokote, Kazumasa Harada, Yasuo Katahira, Takao Uraibe, Yasufumi Uchida, Masaru Hayashi, Naoto Yokota, Hirokazu Nishida, Takatoshi Otonari, Tadashi Arai, Ichiro Sakuma, Kazuo Sakabe, Masayasu Yamamoto, Takashi Kobayashi, Shinichi Oikawa, Shizuya Yamashita, Hirofumi Rakugi, Takumi Imai, Shiro Tanaka, Yasuo Ohashi, Masanari Kuwabara, Hideki Ito</p> | <p>Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized controlled trial</p> | <p>Circulation</p> | <p>140(12)</p> | <p>992-1003</p> | <p>2019</p> |

| | | | | | |
|---|--|------------------------------|---------------|--|-------------|
| <p>Hiroshi Yoshida, Hayato Tada, Kumie Ito, Yoshimi Kishimoto, Hidekatsu Yanai, Hideaki Bujo, Tomonori Okamura, Katsunori Ikewaki, Tetsuo Shoji, Takashi Miida, Masayuki Yoshida, Masafumi Kuzuya, Shizuya Yamashita</p> | <p>Reference intervals of serum non-cholesterol sterols by gender in healthy Japanese individuals</p> | <p>J Atheroscler Thromb.</p> | | <p>doi: 10.5551/jat.50187. [Epub ahead of print]</p> | <p>2019</p> |
| <p>Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Mitsunori Matsushita, Toshiaki Nojima, Hideaki Suganami, Shun Ishibashi</p> | <p>Efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPAαRMa): pooled analysis of phase 2 and 3 studies in dyslipidemic patients with or without statin combination</p> | <p>Int J Mol Sci</p> | <p>20(22)</p> | <p>pii: E5537. doi: 10.3390/ijms20225537</p> | <p>2019</p> |
| <p>Shizuya Yamashita, Hidenori Arai, Hideaki Bujo, Daisaku Masuda, Tohru Ohama, Toshiyuki Ishibashi, Koji Yanagi, Yasuji Doi, Satoshi Nakagawa, Koichi Yamashiro, Kenichiro Tanabe, Toru Kita, Masunori Matsuzaki, Yasushi Saito, Masanori Fukushima, Yujia Matsuzawa, on Behalf of the PROSPECTIVE Study Group</p> | <p>Probuco Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE)</p> | <p>J Atheroscler Thromb.</p> | | <p>doi: 10.5551/jat.55327. [Epub ahead of print]</p> | <p>2020</p> |

| | | | | | |
|---|--|-------------------------------------|--------------|----------------|-------------|
| <p>Kouji Kajinami, Kazuhisa Tsukamoto, Niihari Koba, Ikuo Inoue, Masashi Yamakawa, Shigeaki Suzuki, Tadanori Hamano, Hidetsugu Saito, Yoshiro Saito, Satohiro Masuda, Takeo Nakayama, Tomonori Okamura, Shizuya Yamashita, Takehiro Kagawa, Junji Kaneyama, Akira Kuriyama, Rumi Tanaka, Aya Hirata: Statin Intolerance Clinical Guidelines Working Group; The Japan Society of Hepatology, Japanese Society of Neurology, Japan Atherosclerosis Society, The Japanese Society for the Study of Xenobiotics</p> | <p>Statin intolerance clinical guide 2018</p> | <p>J Atheroscler Thromb</p> | <p>27(4)</p> | <p>375-396</p> | <p>2020</p> |
| <p>Robert Ross, Ian Neelands, Shizuya Yamashita, Iris Shai, Jacob Seidell, Paolo Magni, Raul dos Santos, Benoit Arsenault, Ada Cuevas, Frank Hu, Bruce Griffin, Alberto Zambon, Philip Barter, Jean-Claude Fruchart, Robert Eckel, Yuji Matsuzawa, Jean-Pierre Després</p> | <p>Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity</p> | <p>Nature Reviews Endocrinology</p> | <p>16(3)</p> | <p>177-189</p> | <p>2020</p> |

| | | | | | |
|--|---|-----------------------|-----|---|------|
| Gerald F. Watts, Samuel S. Gidding, Pedro Mata, Jing Pang, David R. Sulivan, Shizuya Yamashita, Frederick J. Raal, Raul D. Santos, Kausik K. Ray | Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care | Nat Rev Cardiol | | doi: 10.1038/s41569-019-0325-8. [Epub ahead of print] | 2020 |
| Daisaku Masuda, Yuko Miyata, Shingo Matsui, Shizuya Yamashita | Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study | Atherosclerosis | 292 | 163-170 | 2020 |
| Yinghong Zhua, Toru Ohama, Ryota Kawase, Jiuyang Chang, Hiroyasu Inui, Kotaro Kanno, Takashi Okada, Daisaku Masuda, Masahiro Koseki, Makoto Nishida, Yasushi Sakata, Shizuya Yamashita | Progranulin deficiency leads to enhanced age-related cardiac hypertrophy through complement C1q-induced β -catenin activation | J Mol Cell Cardiol | 138 | 197-211 | 2020 |
| Daisaku Masuda, Shizuya Yamashita | Postprandial glucose and triglyceride increases along with the endothelial malfunction were attenuated by the administration of SGLT2 inhibitor, empagliflozin | J Atheroscler Thromb. | | doi: 10.5551/jat.ED124. [Epub ahead of print] | 2020 |
| Cesare R Sirtori, Shizuya Yamashita, Maria Francesca Ghecco, Alberto Corsini, Gerald Watts, Massimiliano Rusconi | Recent advances in synthetic pharmacotherapies for dyslipidemias | Eur J Prev Cardiol. | | doi: 10.1177/2047487319845314. [Epub ahead of print] | 2019 |

| | | | | | |
|---|--|----------------------------|--------------|---------------------------------|---------|
| Shizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa | Clinical applications of a novel selective PPAR α modulator, pemafibrate, in dyslipidemia and metabolic diseases | J Atheroscler Thromb | 26(5) | 389-402 | 2019 |
| Shizuya Yamashita, Daisaku Masuda, Yuji Matsuzawa | Review: Pemafibrate, a new selective PPAR α modulator: Drug concept and its clinical applications for dyslipidemia and metabolic diseases | Curr Atheroscler Rep | 22(1):5 | doi: 10.1007/s11883-020-0823-5. | 2020 |
| 小倉正恒 | LDLアフェレシス | 動脈硬化診療のすべて日本医師会雑誌 | 第148巻・特別号(2) | S256-S258 | 2019.10 |
| 小倉正恒 | 家族性高コレステロール血症は正常範囲内の症例も存在すると聞きました。どのような症例で疑い、診断し、そして治療はどのようにすればよいのでしょうか？ | Heart View | Vol.23 No.12 | 54-58 | 2019 |
| 小倉正恒 | HDL機能は測定可能か？ | Heart View | Vol.23 No.8 | 49-54 | 2019 |
| 小倉正恒 | コレステロール恒常性維持に関わるABC A1と疾患・創薬 | 週刊 医学のあゆみ 特集「トランスポーターのすべて」 | Vol.271 No.1 | 4-10 | 2019 |
| 小倉正恒 | 低HDL-C血症の病態と治療意義 | Current Therapy | Vol.37 No.10 | 58-64 | 2019 |
| 小倉正恒 | 家族性高コレステロール血症～診断と治療のポイント～ | Schneller | No.111 | 22-26 | 2019 |
| 小倉正恒, 斯波真理子 | 意外に多い家族性高コレステロール血症のキホンと食事療法のポイント | 臨床栄養 | 第135巻 第1号 | 33-40 | 2019 |
| 小倉正恒 | 家族性高コレステロール血症の診断とリスク評価のためのアキレス腱エコー | 超音波検査技術 | Vol.44 No.4 | 477-485 | 2019 |
| 小倉正恒, 道倉雅仁, 斯波真理子 | 家族性高コレステロール血症超音波によるアキレス腱厚計測の有用性 | 検査と技術 | 第47巻 第10号 | 1174-1177 | 2019 |

| | | | | | |
|---|---|---|----------------|-----------|------|
| 小倉正恒, 斯波真理子 | 家族性高コレステロール血症ホモ接合体におけるアフェレシス:PCSK9阻害薬・MTP阻害薬とのすみわけ | 腎と透析 | Vol.87 No.3 | 475-479 | 2019 |
| Mika Hori, Naotaka Ohta, Atsushi Tanaka, Hiroaki Minakashi, Hiroaki Masuda, Rieko Isoda, Suguru Yamamoto, Cheol Son, Masatsune Ogura, Kiminori Hosoda, Yoshihiro Miyamoto and Mariko Harada-Shiba | Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients | Atherosclerosis | 289 | 101-108 | 2019 |
| Daisuke Sugiyama, Tanvir Chowdhury Turin,3, Fahmidak Yeasmin, Nahid Wumana, Makoto Watanabe, Aya Higashiyama, Misa Takagami, Yoshihiro Kokubo, Tomonori Okamura, Yoshihiro Miyamoto. | Hypercholesterolemia and Lifetime Risk of Coronary Heart Disease in the General Japanese Population : Results from the Suita Cohort Study | Journal of Atherosclerosis and Thrombosis | 27(1) | 60-70 | 2020 |
| 岡崎啓明 | コレステロールとトリグリセリド 遺伝子からの新知見 | New Diet Therapy | 35 | 17-24 | 2019 |
| 岡崎啓明 | 急性膵炎とトリグリセライド | 臨床栄養 | 135 | 61-67 | 2019 |
| 岡崎啓明 | 高TG血症・レムナン | 日本医師会雑誌 | 148 | S89-S93 | 2019 |
| 岡崎啓明 | LDL受容体パステイ | カレントセラピー | 37 | 1007-1007 | 2019 |
| 岡崎啓明 | アポリポ蛋白C-IIとアポリポ蛋白A-V | 臨床病理 | 67 | 1138-1148 | 2019 |
| 小関正博 | "質疑応答 代謝内分泌・糖尿病 HDL-コレステロールが著しく低い症例で注意することは？【LCAT欠損症、魚眼病、タンジール病、アポリポ蛋白A-1欠損症等の遺伝性疾患に注意】" | 週刊 日本医事新報 | No.4983 | 53 | 2019 |

| | | | | | |
|--|--|---------------------------|----------------------------|--|-------------|
| <p>Representatives of the Global Familial Hypercholesterolemia Community, Williamslemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifsawi M, Almahmeed W, Alonso R, Al-Rasadi K, Badimon L, Bernal LM, Bogsrud MP, Braun LT, Brunham L, Catapano AL, Cillíková K, Corral P, Cuevas R, Defesche JC, Descamps OS, de Ferranti S, Eiselé JL, Elikir G, Folco E, Freiburger T, Fuggetta F, Gaspar IM, Geszte s ÁG, Grošelj U, Hamilton-Craig I, Hanauer-Mader G, Harada-Shiba M, Hastings G, Hovingham GK, Izar MC, Jamison A, Karlsson GN, Kayikçioglu M, Koob S, Koseki M, Lane S, Lima-Martinez MM, López G, Martínez TL, Marais D, Marion L, Mata P, Maurina I, Maxwell D, Mehta R, Mensah GA, Miserez AR, Nely D, Nicholls SJ, Nohara A, Nordestgaard BG, Ose L, Pallidis A, Pang J, Payne J, Peterson AL, Popescu MP, Puri R, Ray KK, Reda A, Sampietro T, Santos RD, Schalkers I, Schreier L, Shapiro MD, Sijbrands E, Soffer D, Stefanutti C, Stoll M, Sy RG, Tamayo ML, Tilney MK, Tokgözoğlu L, Tomlinson B, Vallejo-Vaz AJ, Vazquez-Cárdenas A, de Luca PV, Wald DS, Watts GF, Wenger NK, Wolf M, Wood D, Zegerius A, Gaziano TA, Gidding SS.</p> | <p>Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action.</p> | <p>JAMA Cardiol. 2020</p> | <p>Epub ahead of print</p> | | <p>2020</p> |
|--|--|---------------------------|----------------------------|--|-------------|

| | | | | | |
|---|--|--|------------------------|---------|------|
| 小関正博、岡田健志、坂田泰史 | 著名な低HDLコレステロール血症をきたす原発性脂質異常症の臨床的特徴と鑑別 | 日本内科学会雑誌 | 109 | 238 | 2020 |
| Kimura M, Horie T, Baba O, Ide Y, Tsuji S, Ruiz Rodriguez R, Watanabe T, Yamasaki T, Otani C, Xu S, Miyasaka Y, Nakashima Y, Kimura T, Ono K*. | Homeobox A4 suppresses vascular remodeling by repressing YAP/TEAD transcriptional activity. | EMBO Rep. | 21(4) | e48389 | 2020 |
| Ono K*, Wada H, Asahara N, Inoue H, Uehara K, Funada J, Ogo A, Horie T, Fujita M, Shimatsu A, Hasegawa K, on behalf of the ABLE-MET Investigators. | Effects of metformin on left ventricular size and function in hypertensive patients with type 2 diabetes mellitus: results of a randomized, controlled, multicentre, Phase IV trial. | American Journal of Cardiovascular Drugs | Online ahead of print. | | 2019 |
| Ide Y, Horie T, Saito N, Watanabe S, Otani C, Miyasaka Y, Kuwabara Y, Nishino T, Nakao T, Nishiga M, Nishi H, Nakashima Y, Nakazeki F, Koyama S, Kimura M, Tsuji S, Rodriguez RR, Xu S, Yamasaki T, Watanabe T, Yamamoto M, Yanagita M, Kimura T, Kakizuka A, Ono K*. | Cardioprotective Effects of VCP Modulator KUS121 in Murine and Porcine Models of Myocardial Infarction. | JACC Basic Transl Sci. | 4(6) | 701-714 | 2019 |
| Koyama S, Horie T, Nishino T, Baba O, Sowa N, Miyasaka Y, Kuwabara Y, Nakao T, Nishiga M, Nishi H, Nakashima Y, Nakazeki F, Ide Y, Kimura M, Tsuji S, Rodriguez RR, Xu S, Yamasaki T, Otani C, Watanabe T, Nakamura T, Hasegawa K, Kimura T, Ono K*. | The identification of differential roles of microRNA-33a and -33b during atherosclerosis progression with genetically modified mice | J Am Heart Assoc | 8(13) | e012609 | 2019 |

| | | | | | |
|---|--|---|-----------|-----------|------|
| Sakamoto M. Edo N. Takahashi S. Okamura E. Uno K. Morita K. Ishikawa T. Asahi K. Iseki K. Moriyama T. Yamagata K. Tsukamoto K. Fujimoto S. Narita I. Konta T. Konno M. Kimura K. Ohashi Y. Watanabe T. Tsukamoto K. | Association between prescription and control status of dyslipidemia and hypertension among Japanese diabetic patients. | Journal of Atherosclerosis and Thrombosis | 26 | 805-820 | 2019 |
| Kajinami K. Tsukamoto K. Koba N. Inoue I. Yamakawa M. Suzuki S. Hamano T. Saito H. Saito Y. Masuda T. Nakayama T. Okamura T. Yamashita S. Kagawa T. Kaneyama J. Kuriyama A. Tanaka R. Hirata A. Statin Intolerance Clinical Guidelines Working Group. | Statin Intolerance Clinical Guide 2018 | Journal of Atherosclerosis and Thrombosis | 27 | 375-396 | 2020 |
| Kurano M. Kano K. Hara M. Tsukamoto K. Aoki J. Yatomi Y. | Regulation of plasma glycerol-lysophospholipid levels by lipoprotein metabolism. | Biochem J. | 476 | 3565-3581 | 2019 |
| 磯尾直之、塚本和久 | スタチン治療のエビデンス | カレントセラピー | 37 | 943-947 | 2019 |
| 磯尾直之、塚本和久 | スタチン a)薬効 | 日本医師会雑誌 | 148(特別号2) | 222-225 | 2019 |
| 塚本和久 | 冠動脈疾患絶対リスク評価および個別化脂質管理目標値設定のための吹田スコア | 総合健診 | 46 | 480-488 | 2019 |
| 磯尾直之、塚本和久 | 中性脂肪(TG)はどのくらいまで下げる? | 循環器ジャーナル | 67 | 600-607 | 2019 |
| 後藤田貴也 | 栄養・代謝とエイジング | Ageing Science | 12 | 56-59 | 2019 |
| Todate Y, Uwano I, Yashiro S, Chida A, Hasegawa Y, Oda T, Nagasawa K, Honma H, Sasaki M, Ishigaki Y. | High Prevalence of Cerebral Small Vessel Disease on 7T Magnetic Resonance Imaging in Familial Hypercholesterolemia. | J Atheroscler Thromb. | 26(12) | 1045-1053 | 2019 |

| | | | | | |
|--|---|-------------------------------------|---------|--------------------------|------|
| Tada H, Okada H, Nomura A, Yashiro S, Nohara A, Ishigaki Y, Takamura M, Kawashiri MA. | Rare and Deleterious Mutations in ABCG5/ABCG8 Genes Contribute to Mimicking and Worsening of Familial Hypercholesterolemia Phenotype. | Circ J. | 83(9) | 1917-1924. | 2019 |
| Sawada T, Kido J, Yoshida S, Sugawara K, Momosaki K, Inoue T, Tajima G, Sawada H, Matsumoto S, Endo F, Hirose S, Nakamura K. | Newborn screening for Fabry disease in the western region of Japan. | Mol Genet Metab Rep. | 22 | 100562 | 2020 |
| Watanabe S, Kido J, Ogata M, Nakamura K, Mizukami T | Hyperglycemic hyperosmolar state in an adolescent with type 1 diabetes mellitus. | Endocrinol Diabetes Metab Case Rep. | 18-0131 | doi: 10.1530/EDM-18-0131 | 2019 |
| Momosaki K, Kido J, Yoshida S, Sugawara K, Miyamoto T, Inoue T, Okumiyama T, Matsumoto S, Endo F, Hirose S, Nakamura K | Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients. | J Hum Genet | 64(8) | 741-755 | 2019 |
| Kido J, Matsumoto S, Sawada T, Endo F, Nakamura K | Rhabdomyolysis in organic acidemia patients manifesting with metabolic decompensation. | Hemodial Int. | 23 | E115-E119 | 2019 |
| Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, Bright J, Vom Dahl S, Deodato F, Di Rocco M, Göker-Aliapan O, Hughes DA, Lukina EA, Maciagaczka M, Mengel E, Nagral A, Nakamura K, Narita A, Oliveri B, Pastores G, Pérez-López J, Ramaswami U, Schwartz IV, Szer J, Weinreb NJ, Zimran A | Presenting signs and bad patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative. | Intern Med J | 49(5) | 578-591 | 2019 |
| Matsumoto S, Häberle J, Kido J, Mitsubuchi H, Endo F, Nakamura K. | Urea cycle disorder update. | J Hum Genet | 64(9) | 833-847 | 2019 |

| | | | | | |
|--|---|----------------------|----------------|----------|------|
| Suzuki Y, Kido J, Matsumoto S, Shimizu K, Nakamura K | Associations among amino acid, lipid, and glucose metabolic profiles in childhood obesity. | BMC Pediatr. | 19(1) | 273 | 2019 |
| Matsuzaka T, Shimano H. | New perspective on type 2 diabetes, dyslipidemia and non-alcoholic fatty liver disease. | J Diabetes Investig. | 11(3) | 532-534. | 2020 |
| Satoh A, Han SI, Araki M, Nakagawa Y, Ohno H, Mizuno Y, Kumagai K, Murayama Y, Otsuki Y, Iwasaki H, Sekiya M, Konishi M, Itoh N, Matsuzaka T, Sone H, Shimano H. | CREBH Improves Diet-Induced Obesity, Insulin Resistance, and Metabolic Disturbances by FGF21-Dependent and FGF21-Independent Mechanisms | iScience. | 23(3):1009-30. | - | 2020 |
| Manda CM, Hokimoto T, Okura T, Ishida H, Shimano H, Wagatsuma Y. | Handgrip Strength Predicts New Prediabetes Cases Among Adults: A Prospective Cohort Study | Prev Med Rep | 17:101056. | - | 2020 |
| Kawasaki M, Kamabe A, Yamamoto Y, Arulmozhiraja S, Ito S, Nakagawa Y, Tokiwa H, Nakano S, Shimano H. | Elucidation of Molecular Mechanism of a Selective PPAR α Modulator, Pemafibrate, Through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations | Int J Mol Sci | 21(1):361. | - | 2020 |

| | | | | | |
|--|--|----------------------|---------------|------------|------|
| Matsuzaka T, Kubo M, Koyasu S, Yamamoto Y, Motomura K, Arulmozhiraja S, Ohno H, Sharma R, Shimura T, Okajima Y, Hanty SI, Aita Y, Mizunoe Y, Osaki Y, Iwasaki H, Yatoh S, Suzuki H, Sone H, Takeuchi Y, Yahagi N, Miyamoto T, Sekiya M, Nakagawa Y, Ema M, Takahashi S, Tokiwa H, Shimano H. | Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice | Hepatology. | 71(5): | 1609-1625. | 2020 |
| Fruchart JC, Santos RD, Yamashita S, Libby P; International Atherosclerosis Society/R3i Foundation Consensus Panel. | Residual Vascular Risk in Diabetes - Will the SPPARM Alpha Concept Hold the Key? | Diabetes Metab Syndr | 13(4): | 2723-2725. | 2019 |
| Mizunoe Y, Kobayashi M, Tagawa R, Nakagawa Y, Shimano H, Higami Y. | Association Between Lysosomal Dysfunction and Obesity-Related Pathology: A Key Knowledge to Prevent Metabolic Syndrome | Int J Mol Sci | 20(15):368-8. | | 2019 |

| | | | | | |
|--|--|----------------------|-----------|---------|------|
| Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Després JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Núñez-Cortés JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Pontanegretti CI, Pradhan A, Ray KK, Reinher Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sirtara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskiran MR, Tenenbaum A, Tokgözoğlu L S, Tomlinson B, Tybjaerg-Hansen A, Valensi P, Vrablík M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P. | The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARMα) Paradigm: Conceptual Framework and Therapeutic Potential : A Consensus Statement From the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation | Cardiovasc Diabetol. | 18(1):71. | - | 2019 |
| 稲垣恭子 | 糖尿病におけるリポ蛋白代謝異常とその治療 | 医学のあゆみ | 268 | 410-414 | 2019 |
| Yoshida H, Tada H, Ito K, Kishimoto Y, Yanai H, Okamura T, Ikewaki K, Inagaki K, Shoji T, Bujo H, Miida T, Yoshida M, Kuzuya M, Yamashita S. | Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals. | J Atheroscler Thromb | 1;27(5) | 409-417 | 2019 |

学会発表

| 発表者氏名 | 発表演題名 | 学術集会名 |
|--|--|--|
| Kuroda M, Yamamoto T, Yokote K, Saito Y, Aso M. | Gene/Cell Therapy for familial LCAT deficiency by Genetically Modified Adipocytes, GMAC. | 3rd Annual cell therapy World ASIA 2019. |
| 武城 英明、小関 正博、黒田正幸、村野 武義、中司 敦子、和田 淳、竹内 康雄、石川 耕、横手 幸太郎、山下 静也.. | 低HDL-C血症の診断の進め方-LCAT欠損症とタンジール病. | 第51回日本動脈硬化学会総会・学術集会シンポジウム. |
| 仲村武裕、中山良朗、照屋理子、本間健一郎、屋比久賢光、照屋太輝、池間朋己、黒田正幸、石川耕、横手幸太郎、益崎裕章 | 低HDL-C血症、角膜混濁により家族性LCAT欠損症と遺伝子診断した1例. | 第40回 日本肥満学会. |
| 吉田晃浩、幸脇正明、木下慎介、高山哲夫、黒田正幸、石川耕、横手幸太郎、内藤通孝. | 二十数年を経て再評価できたLCAT欠損症の1例. | 第51回日本動脈硬化学会総会・学術集会. |
| 仲村武裕、中山良朗、照屋理子、本間健一郎、屋比久賢光、照屋太輝、難波豊隆、池間朋己、黒田正幸、石川耕、横手幸太郎、益崎裕章. | 低HDL-C血症、角膜混濁により家族性LCAT欠損症と遺伝子診断した1例. | 第92回 日本内分泌学会学術総会. |